Changes

Jump to: navigation, search

Chronic myelomonocytic leukemia

456 bytes added, 22:27, 18 August 2018
m
Text replacement - "{| class="wikitable" style="width: 100%; text-align:center;" !Study !Evidence !Comparator !Efficacy |-" to "{| class="wikitable" style="width: 100%; text-align:center;" !style="width: 25%"|Study !style="width: 25%"|Evidence !style="width: 25%"|Comparator !style="width: 25%"|Efficacy |-"
===Variant #1, 7 days {{#subobject:bad5a2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!style="width: 25%"|Study!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]!style="width: 25%"|Comparator!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
===Variant #2, 5-2-2 {{#subobject:38dc01|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!style="width: 25%"|Study!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]!style="width: 25%"|Comparator!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nature.com/leu/journal/v28/n7/full/leu201485a.html Drummond et al. 2014]
===Variant #1, 7 days of azacitidine {{#subobject:dbee1c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!style="width: 25%"|Study!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]!style="width: 25%"|Comparator!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
===Variant #2, 5-2-2 azacitidine {{#subobject:8be395|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!style="width: 25%"|Study!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]!style="width: 25%"|Comparator!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
===Variant #1, 7 days of azacitidine {{#subobject:68c3a6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!style="width: 25%"|Study!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]!style="width: 25%"|Comparator!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
===Variant #2, 5-2-2 azacitidine {{#subobject:fbb1d5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!style="width: 25%"|Study!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]!style="width: 25%"|Comparator!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
LookupUsers, editors, emailconfirmed, Administrators
14,670
edits

Navigation menu